REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
REGN is not a good buy right now for an impatient investor. Despite a clear earnings beat and very bullish Wall Street price-target momentum, the near-term technical setup is weak (bearish MACD, sub-40 RSI) and short-horizon pattern-based odds skew to further downside. With insiders selling aggressively and no proprietary “strong buy” signal today, the risk/reward favors waiting rather than buying immediately at ~$750.
Price/Trend: REGN is hovering around the pivot (~748) after earnings, but momentum is currently soft. Momentum: MACD histogram is negative (-2.812) and expanding lower, which typically signals bearish momentum building rather than stabilizing. RSI: RSI(6) ~38.7, leaning toward weak/near-oversold; it can bounce from here, but it’s not yet a confirmed reversal. Moving averages: Converging MAs suggest consolidation/indecision rather than a clean uptrend continuation. Key levels: Pivot 748.4 is the immediate decision point. A sustained move above R1 ~770.5 would improve the setup; losing pivot opens the door toward S1 ~726.3 (then S2 ~712.6). Quant/pattern risk: Similar-pattern analysis implies elevated downside risk (-8% next day, -13% next week, -15% next month), which argues against immediate entry.
Intellectia Proprietary Trading Signals
and revenue (~$3.9B) beat expectations, supporting confidence in fundamentals.
Near-term technical weakness: Bearish MACD expansion + RSI below 40 suggests downside pressure may persist before a durable bounce.
Insider behavior: Insiders are reported selling, with selling amount up ~327% over the last month (a sentiment overhang near-term).
Earnings quality optics: Q4 earnings down YoY (profit decline), even though the quarter beat expectations.
Short-horizon downside skew: Pattern-based probability distribution points to higher odds of drawdown over the next day/week/month, which is unfavorable for an impatient entry.
Latest quarter season (Q4 2025, reported 2026-01-30 pre-market): Non-GAAP/adjusted EPS $11.44 (about -5% YoY) but materially above consensus; revenue about $3.9B, also above expectations—operationally strong quarter despite YoY EPS decline.
Most recent provided detailed snapshot (2025/Q3): Revenue +0.9% YoY to $3.754B; Net income +8.9% YoY to ~$1.46B; EPS +18.0% YoY to 13.62; gross margin slightly down (86.1%, -0.79% YoY). Overall: modest top-line growth with strong EPS leverage, though margins softened slightly.
Trend (recent): Strongly improving. Since early January, multiple price-target raises and a notable BofA upgrade to Buy (from Underperform) highlight a clear shift more bullish, largely tied to Eylea HD expectations, price actions, and continued confidence in Dupixent/collaboration economics. Wall Street pros: (1) Upside narrative around Eylea HD competitiveness/label updates and launch acceleration, (2) durable growth contribution from Dupixent, (3) potential pipeline upside in 2026. Wall Street cons: (1) Prior Eylea SD erosion concerns still frame the debate (even if consensus has reset), (2) YoY earnings pressure can cap near-term multiple expansion, (3) post-earnings digestion risk given the already-strong run into results. Influential/Political flows: No recent congress trading data available in the last 90 days.
